Health Care · Laboratory Analytical Instruments · NYSE · CIK 1722482 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $14.38Day +15.78%Mkt cap $9.8B1Y +2.6%Off 52W high −9.7%Vol (1Y) 54.6%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,805 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Price impliesNEVER-OBSERVED · 90.5% growth |
| Short interest8.2% of sh out |
| Days to cover6.5d |
| 13F net flow (QoQ)−7.26% |
| Top-10 13F concentration55.3% |
| Next report (est.)2026-10-28 |
Fair value, confidence and the reverse-DCF grade are the MATERIALIZED daily snapshot (the same columns the screener serves), not a live model run. Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$6.55B |
| Earnings (TTM)-$551.4M |
| ROE−9.2% |
| Net margin−8.1% |
| ROIC−2.1% |
| Debt / equity0.71× |
| YTD+25.5% |
| 1Y+2.6% |
| 3Y−30.1% |
| 5Y−61.4% |
| Since incept. (ann.)−0.1% |
Total return through 2026-07-29 · series begins 2019-05-17. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)54.6% |
| Ann. volatility (3Y)43.7% |
| Sharpe (1Y)0.33 |
| Sharpe (3Y)−0.08 |
| Max drawdown (1Y)−52.5% |
| Max drawdown (3Y)−73.2% |
| Beta (3Y vs SPY)0.85 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Dodge & Cox | 119.6M | $938M | 17.52% | +2.2% |
| BlackRock, Inc. | 65.7M | $515M | 9.62% | +10.2% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 31.3M | $245M | 4.58% | new |
| VANGUARD CAPITAL MANAGEMENT LLC | 30.6M | $240M | 4.48% | new |
| WELLINGTON MANAGEMENT GROUP LLP | 24.2M | $190M | 3.55% | +3.4% |
| GREENHAVEN ASSOCIATES INC | 22.6M | $177M | 3.31% | +10.2% |
| BARROW HANLEY MEWHINNEY & STRAUSS LLC | 22.4M | $175M | 3.27% | −32.8% |
| STATE STREET CORP | 20.7M | $162M | 3.03% | +2.5% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-04-29 | $0.06 | −33.3% | $1.58B | +0.0% |
| 2025-12-31 | 2026-02-11 | — | — | $1.66B | −1.4% |
| 2025-09-30 | 2025-10-29 | −$1.04 | −1400.0% | $1.62B | −5.3% |
| 2025-06-30 | 2025-08-01 | $0.09 | −35.7% | $1.68B | −1.1% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-10-28 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Proprietary Materials And Consumables 53% · Third Party Materials And Consumables 47%
product & service · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
| Total debt / EBITDA24.06× |
| Sales growth 3Y−4.5% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
